Moderate Alcohol Intake Reduces Lymphoma Risk, Says UK Study

A new study published in the British Journal of Cancer suggests that moderate alcohol intake is associated with a reduced risk of a number of frequently-diagnosed subtypes of lymphoma.

The study used data from the Million Women's Study, a United Kingdom-based study that recruited about 1.3 million middle-aged women between 1996 and 2009 (women were followed for an average of 10.3 years) until death emigration or cancer registration. Any risk factors they had were assessed by way of questionnaire, and the adjusted relative risks were estimated by Cox regression.

The Million Women Study collaborators recorded 9,162 incident cases of hematological cancers in follow-up, along with 2,072 myeloid cancers.

What they found was that among predominantly "moderate alcohol drinkers," those with higher alcohol intake had a lowered risk of developing either diffuse large B-cell lymphoma (which is the most frequently diagnosed non-Hodgkin's lymphoma) or follicular lymphoma (which is the second most frequently diagnosed non-Hodgkin's lymphoma).

They also determined a reduced risk among those same recruits for developing plasma cell cancers, such as multiple myeloma or acute myeloid leukemia.

It should come as no surprise that they also found that higher cigarette consumption was associated with an increased risk of Hodgkin's lymphoma, mature T-cell lymphomas and myelodysplastic syndrome (MDS), once known as pre-leukemia. MDS can develop into aggressive AML.

Researchers believe that future research should be conducted into what the mechanism might be that allows moderate consumption of alcohol to lower one's risk of myelomas and certain B-cell lymphomas.

Source: BJC

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap